Results 11 to 20 of about 387,299 (303)

Сomparative Study of Progepar Efficacy in Patients with Non-Alcoholic Steatohepatitis

Gastroenterologìa, 2015
Non-alcoholic fatty liver disease is one of the most common pathologies of the liver in developed countries. On the average, its prevalence reaches 20 %.
V.G. Perederii, G.K. Syzenko
doaj   +2 more sources

Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?

The Korean Journal of Gastroenterology, 2016
Articles: Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-cirrhotic, Non-alcoholic Steatohepatitis (FLINT): a Multicentre, Randomised, Placebo-controlled Trial (Lancet 2015;385:956-965) Liraglutide Safety and Efficacy in Patients with Non ...
Nae-Yun Heo
doaj   +2 more sources

Therapies for non-alcoholic steatohepatitis

Liver Research, 2017
Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and ...
Winston Dunn
doaj   +2 more sources

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges [PDF]

Gut, 2020
Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years.
J. Dufour, C. Caussy, R. Loomba
semanticscholar   +3 more sources

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients

Indian Journal of Pathology and Microbiology, 2010
Background: Alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH) are significant forms of liver disease and may progress to end-stage liver disease, cirrhosis and potentially malignant complications.
Singh Deepak, Rastogi Archana, Sakhuja Puja, Gondal Ranjana, Sarin Shiv   +4 more
doaj   +1 more source

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

Journal of Hepatology, 2021
Background and Aims: Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) is increasing globally, but its molecular features are not well defined.
R. Pinyol, S. Torrecilla, Huan Wang, C. Montironi, M. Piqué-Gili, M. Torres-Martín, Leow Wei-Qiang, Catherine E. Willoughby, P. Ramadori, C. Andreu-Oller, Patricia Taik, Youngmin A. Lee, Agrin Moeini, J. Peix, Suzanne Faure-Dupuy, T. Riedl, Svenja Schuehle, C. Oliveira, V. Alves, P. Boffetta, A. Lachenmayer, S. Roessler, B. Mínguez, P. Schirmacher, J. Dufour, S. Thung, H. Reeves, F. Carrilho, Charissa Y. Chang, A. Uzilov, M. Heikenwalder, A. Sanyal, S. Friedman, D. Sia, J. Llovet   +34 more
semanticscholar   +1 more source

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu, Frank J. Gonzalez   +22 more
wiley   +1 more source

Development and Validation of a Score for Fibrotic Non-Alcoholic Steatohepatitis.

Clinical Gastroenterology and Hepatology, 2022
BACKGROUND AND AIMS Non-invasive assessment of histological features of non-alcoholic fatty liver disease (NAFLD) has been an intensive research area over the last decade.
F. Tavaglione, O. Jamialahmadi, A. De Vincentis, S. Qadri, M. Mowlaei, R. Mancina, E. Ciociola, S. Carotti, G. Perrone, V. Bruni, I. Gallo, D. Tuccinardi, C. Bianco, D. Prati, S. Manfrini, P. Pozzilli, A. Picardi, M. Caricato, H. Yki-Järvinen, Luca Valenti, U. Vespasiani-Gentilucci, S. Romeo   +21 more
semanticscholar   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression

Nature Communications, 2022
Spermidine is a natural polyamine that has health benefits and extends life span in several species. Deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH) are key enzymes that utilize spermidine to catalyze the post-translational ...
Jin Zhou, J. Pang, M. Tripathi, Jia-Pei Ho, A. Widjaja, Shamini G Shekeran, S. Cook, A. Suzuki, A. Diehl, E. Petretto, B. Singh, P. Yen   +11 more
semanticscholar   +1 more source